Previous 10 | Next 10 |
FibroGen, Inc. (FGEN) Q2 2021 Results Conference Call August 9, 2021 5:00 PM ET Company Participants Michael Tung - Vice President of Corporate Strategy and Investor Relations Enrique Conterno - Chief Executive Officer Pat Cotroneo - Chief Financial Officer Mark Eisner - Chief Medical Officer...
• Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. • Total roxadustat net sales in China of $52.8 million 1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca • Roxadustat R...
SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2021 financial results on Monday, August 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment comm...
FibroGen (NASDAQ: FGEN) received some bad news recently with an overwhelmingly negative vote by a U.S. Food and Drug Administration (FDA) advisory committee related to anemia drug roxadustat. In this Motley Fool Live video recorded on July 19, 2021 , healthcare and cann...
Shares of FibroGen Inc (NASDAQ:FGEN) traded today at $12.94, breaking its 52-week low. So far today approximately 1.3 million shares have been exchanged, as compared to an average 30-day volume of 1.7 million shares. FibroGen Inc is a biotechnology company focused on discovering, develop...
China-based venture capital firm Qiming has raised more than $500 million to invest in shares of listed healthcare companies. The Springhill Fund, as it is called, will have an initial regional focus on Greater China and Asia. Shanghai Junshi Bio formed an mRNA Joint Venture with Hang...
Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic Cornea Clinical Stage Asset Has Potential for First Approved Biosynthetic Human Cornea Biosynthetic Cornea Designed to Address Significant Unmet Need in Gl...
FibroGen (NASDAQ: FGEN) stock imploded Friday after an FDA advisory panel voted Thursday against approving the company's lead drug candidate, roxadustat. Shares of the biotech were down by around 46% as of 1:20 p.m. EDT. The FDA convened a panel of independent experts Thursday a...
Gaiers: TD Holdings (GLG) +45%.GX Acquisition (GXGX) +40%.China SXT Pharmaceuticals (SXTC) +35%.Newegg Commerce (NEGG) +17%.Orphazyme (ORPH) +17%.TDH Holdings (PETZ) +16%.Aehr Test Systems (AEHR) +14%.Byrna Technologies (BYRN) +13%.Jewett-Cameron Trading Company (JCTCF) +13%.CooTek (Cayman) (...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TD Holdings (NASDAQ: GLG ) stock is rising higher on Friday after announcing plans to acquire two companies. Source: Shutterstock.com According to a press release , TD Holdings has signed a non-binding Letter...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...